AstraZeneca Will Acquire Verus Asthma Program In Deal Worth $310 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement will allow AstraZeneca to continue building its pediatric respiratory franchise, firm tells "The Pink Sheet" DAILY.
You may also be interested in...
Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug
Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.
Verus Sues AstraZeneca For $1.28B Over Deals To Develop Pediatric Asthma Drug
Verus claims that it is being “destroyed” by AstraZeneca’s move to terminate a high-value pediatric asthma deal.
MAP Enters Phase III For Pediatric Asthma Candidate, Targets AstraZenica’s Pulmicort
California firm says its unit-dose formulation of budesonide offers smaller dose, quicker nebulization through micro-particle technology.